1. RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer 
Matthew R. Smith 
European Urology Supplements 
Volume 8, Issue 11, Pages (November 2009)
DOI: /j.eursup
Copyright © 2009 European Association of Urology Terms and Conditions

2. Fig. 1
Time to first fracture in men with nonmetastatic prostate cancer receiving gonadotropin-releasing hormone (GnRH) agonists compared with controls. Redrawn with permission from the American Society of Clinical Oncology [8].
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

3. Fig. 2
Effect of denosumab (60mg every 6 mo) on (a) total hip and (b) femoral neck bone mineral density in men receiving androgen-deprivation therapy compared with placebo. Values are mean plus or minus 95% confidence interval. Adapted with permission from the Massachusetts Medical Society [22].
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

4. Fig. 3
Incidence of new vertebral fractures during 3 yr of treatment with denosumab or placebo in men receiving androgen-deprivation therapy. Adapted with permission from the Massachusetts Medical Society [22].
RR=relative risk.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

5. Fig. 4
Design of an ongoing study assessing the ability of denosumab to improve bone metastases–free survival in men receiving androgen-deprivation therapy.
s.c.=subcutaneous; Q4W=every 4 wk.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

6. Fig. 5
Ongoing investigations may show benefits of denosumab at various points in the progression of prostate cancer.
PSA=prostate-specific antigen; SRE=skeletal-related event; ADT=androgen-deprivation therapy; HRPC=hormone-refractory prostate cancer.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions